title: Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
abstract: OBJECTIVE
  This phase II investigated efficacy and tolerability of gefitinib in combination with paclitaxel (P) and carboplatin (C) for second-line treatment of patients (pts) with ovarian, tubal or peritoneal adenocarcinoma.
  
  
  METHODS
  Women (>18 years) with platinum-resistant/refractory (relapsed<6 months), or platinum-sensitive (relapsed >6 months) disease after first-line platinum-based and P chemotherapy. Pts received 6-8 cycles of gefitinib (500 mg/day), P (175 mg/m(2) 3 h infusion) and C (AUC 5) every 3 weeks, followed by gefitinib alone. The primary endpoint was objective response rate (ORR) (RECIST or Rustin criteria).
  
  
  RESULTS
  Sixty-eight patients (26 resistant/refractory and 42 sensitive) were enrolled (median age: 57 years). ORR and disease control rates were 19.2% and 69.2% for resistant/refractory, and 61.9% and 81.0%, for sensitive disease. Median time to progression and overall median survivals were 6.1 and 16.9 months for resistant/refractory and 9.2 and 25.7 months for sensitive disease. Grade 3/4 toxicities (in > or = 10% patients) were neutropenia (59%), diarrhea (25%), leukopenia (22%), anemia (13%), and acne (13%). Two secondary myelodysplastic syndromes (MDS) and one secondary acute leukemia occurred during treatment, and one MDS 34 months after treatment discontinuation.
  
  
  CONCLUSIONS
  Gefitinib, administered in combination with paclitaxel and carboplatin, provides a good clinical response but associated with an increased risk of hematologic disorders.
authors.affiliation: Department of Medical Oncology, Institut Gustave-Roussy, 39 rue Camille-Desmoulins, 94805 Villejuif, France. pautier@igr.fr
authors.forename: Patricia
authors.initials: P
authors.lastname: Pautier
authors.forename: Florence
authors.initials: F
authors.lastname: Joly
authors.forename: Pierre
authors.initials: P
authors.lastname: Kerbrat
authors.forename: Philippe
authors.initials: P
authors.lastname: Bougnoux
authors.forename: Pierre
authors.initials: P
authors.lastname: Fumoleau
authors.forename: Thierry
authors.initials: T
authors.lastname: Petit
authors.forename: Olivier
authors.initials: O
authors.lastname: Rixe
authors.forename: François
authors.initials: F
authors.lastname: Ringeisen
authors.forename: Annie Tisseron
authors.initials: AT
authors.lastname: Carrasco
authors.forename: Catherine
authors.initials: C
authors.lastname: Lhommé
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D011799:Quinazolines; D016190:Carboplatin; D017239:Paclitaxel; D000077156:Gefitinib